Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1142692

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 April 2019 to Question 236381, what steps NHS England has taken to fill the gap left by the closure of the Commissioning Support Programme for treatments that are awaiting review by the Clinical Priorities Advisory Group.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	284181
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>Further to the answer the Minister of State for Care (Caroline Dinenage MP) gave on 2 April 2019 to Question 236381, that NHS England has considered this issue, and does not believe that a gap has been created as a result of the closure of Commissioning Support Programme for treatments that are awaiting review by the Clinical Priorities Advisory Group.</p><p>The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme.</p><p>All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage for post stakeholder testing. These are now being progressed though the usual development process. Further information is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/" target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p><p> </p><p> </p><p> </p> answering member constituency Kingswood answering member printed Chris Skidmore grouped question UIN 284182 question first answered 09/09/2019 18:52:46 answering member 4021 label Biography information for Chris Skidmore
tabling member	4131 label Biography information for Jim Shannon

1142693

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect on treatments within NHS England’s Clinical Commissioning Policy programme of the closure of the Commissioning Support Programme; and if he will make a statement.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	284182
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>Further to the answer the Minister of State for Care (Caroline Dinenage MP) gave on 2 April 2019 to Question 236381, that NHS England has considered this issue, and does not believe that a gap has been created as a result of the closure of Commissioning Support Programme for treatments that are awaiting review by the Clinical Priorities Advisory Group.</p><p>The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme.</p><p>All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage for post stakeholder testing. These are now being progressed though the usual development process. Further information is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/" target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p><p> </p><p> </p><p> </p> answering member constituency Kingswood answering member printed Chris Skidmore grouped question UIN 284181 question first answered 09/09/2019 18:52:46 answering member 4021 label Biography information for Chris Skidmore
tabling member	4131 label Biography information for Jim Shannon

1142749

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the budget is for products undergoing review via the NHS England prioritisation process in 2020-21.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	284324
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>NHS England has not yet been set the budget for products undergoing review via the NHS England prioritisation process in 2020-21.</p> answering member constituency Kingswood answering member printed Chris Skidmore question first answered 09/09/2019 18:37:16 answering member 4021 label Biography information for Chris Skidmore
tabling member	4131 label Biography information for Jim Shannon